|Rhinitis, Allergic, Seasonal Rhinitis, Allergic, Perennial Urticaria||Drug: Desloratadine Syrup|
|Study Design:||Observational Model: Ecologic or Community
Time Perspective: Prospective
|Official Title:||Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Syrup Among Filipino Pediatric Patients|
The participant's global assessment of tolerability with the medication was assessed using a categorical scale as follows:
Parent or guardian of each participant followed up for a final visit after 14 days (Day 15) at which tolerability was rated and reported for entire treatment period. Number of participants in each category is presented.
|Study Start Date:||March 2008|
|Study Completion Date:||May 2010|
|Primary Completion Date:||May 2010 (Final data collection date for primary outcome measure)|
Participants with allergic rhinitis or idiopathic urticaria
Outpatient pediatric participants (ages 6 months-11 years) in the Philippines with a diagnosis of allergic rhinitis or chronic idiopathic urticaria.
Drug: Desloratadine Syrup
Desloratadine (Aerius) Syrup;
Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:
Other Name: Aerius, Clarinex, SCH 34117, descarboethoxyloratadine